Probiotics for Vaginal Health

Verdict: Published with Warning

Across 6 PubMed studies, the evidence for Probiotics in Vaginal Health grades Tier B — preliminary evidence. Effective, but with safety or population caveats.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.63
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
88%
Highly consistent evidence
Evidence level
E1
Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.42
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.65
L2 PubMedPrimary literature
0.75
L3 MechanismPlausibility
0.75
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.632
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 1 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (6)L2 · primary research & systematic reviews

Probiotics for the treatment of bacterial vaginosis
PMID: 19821358 2009 Cochrane Review
Finding: Across 4 small trials the review found no conclusive benefit of probiotics over or added to antibiotics; two combination regimens looked promising (metronidazole+probiotic OR 0.09; probiotic/estriol OR 0.02 for microbiological cure) but evidence was deemed insufficient.
🟢 High quality Academic Effect size: Insufficient evidence overall; promising sub-results metronidazole+probiotic OR 0.09, probiotic/estriol OR 0.02
View on PubMed
Probiotics are a good choice for the treatment of bacterial vaginosis: a meta-analysis of randomized controlled trial
PMID: 35698149 2022 統合分析 n = 2,093
Finding: Probiotics added to antibiotics modestly improved cure rate vs antibiotics alone (RR 1.23, 95% CI 1.05-1.43, p=0.009), whereas probiotics vs antibiotics showed no difference (RR 1.12, 95% CI 0.60-2.07, p=0.72).
Government Effect size: Probiotics+antibiotics vs antibiotics RR 1.23 (95% CI 1.05-1.43)
View on PubMed
Probiotics, a promising therapy to reduce the recurrence of bacterial vaginosis in women? A systematic review and meta-analysis of randomized controlled trials
PMID: 36204368 2022 統合分析 n = 1,234
Finding: Probiotics reduced BV recurrence risk by ~45% versus placebo/antibiotic-alone (RR 0.55, 95% CI 0.33-0.91, p=0.03).
Academic Effect size: RR 0.55 (95% CI 0.33-0.91)
View on PubMed
Antibiotics therapy combined with probiotics administered intravaginally for the treatment of bacterial vaginosis: A systematic review and meta-analysis
PMID: 37724125 2023 統合分析 n = 1,493
Finding: Adding intravaginal probiotics to antibiotics lowered recurrence at 12-16 weeks (RR 0.62, 95% CI 0.45-0.85) versus antibiotics plus placebo.
Effect size: Recurrence RR 0.62 (95% CI 0.45-0.85)
View on PubMed
Effectivity and efficacy probiotics for Bacterial Vaginosis treatments: Meta-analysis
PMID: 36262267 2022 統合分析 n = 1,534
Finding: Reported a statistically significant higher cure rate and lower recurrence rate favoring probiotics, but the paper does not provide pooled RR/OR with confidence intervals, limiting interpretability.
🟠 Limited quality Effect size: Significant favoring probiotics; no pooled RR/OR with CI reported
View on PubMed
Comparative efficacy of oral and vaginal probiotics in reducing the recurrence of bacterial vaginosis: a double-blind clinical trial
PMID: 39462408 2024 RCT (double-blind) n = 66
Finding: Both oral and vaginal probiotics significantly reduced Nugent scores within group (9->3 and 8.5->3, p<0.001), with no significant difference between routes (between-group p=0.053); the trial had no placebo arm.
🟠 Limited quality Academic Effect size: Within-group Nugent reduction p<0.001; between-route difference p=0.053 (NS)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
FDA has not approved any probiotic product for use as a drug or biological product in infants of any age source↗
L4b EU EFSA
Against
a cause and effect relationship had not been established between the consumption of a combination of bacterial strains and reduction of gastro-intestinal discomfort source↗
L4c UK NHS
Cautious
There's some evidence that probiotics may be helpful in some cases, such as helping to ease some symptoms of irritable bowel syndrome (IBS). But there's little evidence to support many health claims made about them. source↗
L4d TW TFDA / 衛福部
Supportive
益生菌屬食品,並無治療疾病的效果 source↗
L4e WHO
Neutral
probiotic supplementation with the strains Bifidobacterium longum subsp. Infantis DSM33361 and Lactobacillus rhamnosus GG source↗
L5a NIH Office of Dietary Supplements
Supportive
Probiotics might reduce some symptoms of IBS. source↗
L5b Mayo Clinic
Cautious
Vaginal probiotics are supplements that can be inserted into the vagina or taken orally, and they're said to support the bacteria in the vagina — just like probiotics support bacteria in the gut. However, there is no evidence that a probiotic will improve the bacterial mix in the vagina. source↗
L5c Cleveland Clinic
Supportive
The vaginal application of Lactobacillus crispatus after treatment of BV with a topical antibiotic decreased recurrence for three months after the last dose of the probiotic. ... I recommend reading the labels and confirming it has Lactobacillus crispatus and or Lactobacillus rhamnosus amongst the other Lactobacillus in the probiotic. ... While probiotics don't have any side effects, make sure … source↗
L5d Harvard Health
Cautious
only 30% of the Lactin-V group had a recurrence of bacterial vaginosis by week 12, compared with 45% of the placebo group source↗
L5e Specialty Society (condition-mapped)
Against
Studies have evaluated the clinical and microbiologic efficacy of intravaginal Lactobacillus and other probiotic formulations to treat BV and restore normal vaginal microbiota; overall, no studies support these products as an adjunctive or replacement therapy for women with BV. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬6 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-vaginal-health-INT-probiotics-001 繁體中文版 →